Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS National Framework Agreement for Omalizumab

NHS England

This public procurement record has 4 releases in its history.

Award

30 Dec 2025 at 16:29

UK7 - Contract Details Notice
Award

28 Nov 2025 at 12:23

UK6 - Contract Award Notice
Tender

03 Oct 2025 at 08:53

UK4 - Tender Notice
Planning

26 Aug 2025 at 17:01

UK2 - Preliminary Market Engagement Notice
Summary of the contracting process

The NHS National Framework Agreement for Omalizumab, managed by NHS England, has been finalised through an open procurement procedure. The project is classified under the pharmaceutical products industry and has a framework period starting from 1st February 2026 to 31st August 2027, with potential extensions at the Authority's discretion for up to 24 additional months. The framework aims to provide Omalizumab across different regions in the UK, with NHS England at Wellington House, London serving as the buyer. The most recent update indicates that the procurement process has reached the contract award stage, with significant activity marked on dates such as 30th December 2025, reflecting the finalisation of contractual agreements with successful suppliers.

This procurement presents substantial opportunities for businesses operating in the pharmaceutical sector, particularly those specialising in the supply of pharmaceutical products like Omalizumab. Large-scale suppliers such as Celltrion Healthcare United Kingdom Limited, Mercury Pharmaceuticals Limited, and Novartis Pharmaceuticals UK Limited have already been successful in engaging with this tender. This contract is particularly beneficial for established pharmaceutical companies that can meet stringent supply chain requirements and are capable of managing extensive frameworks. Smaller enterprises may not find it as accessible due to the scale required, yet the prospect of future framework agreements or extensions allows room for growth and expansion within public sector collaborations.

How relevant is this notice?

Notice Information

Notice Title

NHS National Framework Agreement for Omalizumab

Notice Description

Project title: NHS National Framework for Omalizumab commencing 1st February 2026 Offer reference number: CM/TNS/25/5734 Period of framework: 1 February 2026 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Lot Information

Lot 1

Renewal: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Planning Information

NHS England is seeking to engage with suppliers that are planning to launch Omalizumab injection. Interested suppliers will be invited to a virtual PME meeting to be held on Thursday 18th September 2025 The purpose of these sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, and KPI's. Please contact katie.noonan@nhs.net or marie.graney1@nhs.net to register your interest in tendering for this framework.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-058e04
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/086501-2025
Current Stage
Award
All Stages
Planning, Tender, Award

Procurement Classification

Notice Type
UK7 - Contract Details Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
SME
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£85,785,000 £10M-£100M
Lots Value
£85,785,000 £10M-£100M
Awards Value
£87,433,000 £10M-£100M
Contracts Value
£87,433,000 £10M-£100M

Notice Dates

Publication Date
30 Dec 20257 months ago
Submission Deadline
30 Oct 2025Expired
Future Notice Date
1 Oct 2025Expired
Award Date
26 Nov 20259 months ago
Contract Period
1 Feb 2026 - 31 Aug 2027 1-2 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Active, Pending
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
TLC North East (England), TLD North West (England), TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLJ South East (England), TLK South West (England)
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
3
Supplier Names

CELLTRION HEALTHCARE UNITED KINGDOM LIMITED

MERCURY PHARMACEUTICALS LIMITED

NOVARTIS PHARMACEUTICALS UK LIMITED

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...